Cytec Industries Inc. v Nalco Company (No 4)

Link copied
Case Copied 49 min read

FEDERAL COURT OF AUSTRALIA

Cytec Industries Inc. v Nalco Company (No 4) [2024] FCA 1318

Appeal from: Cytec Industries Inc. v Nalco Company [2019] APO 2
File number(s): NSD 130 of 2019
Judgment of: BURLEY J
Date of judgment: 15 November 2024
Catchwords:

PATENTS – application to amend patent application following determination of appeal under s 60(4) of the Patents Act 1990 (Cth) – whether proposed amendments allowable under s 102 of the Patents Act – application refused

PATENTS – whether proposed amendments overcome deficiencies identified on appeal from opposition proceedings – lack of support – lack of clear and complete description

PATENTS – claim construction – whether claims include within their scope a reaction product mixture containing only the named small molecules

Legislation:

Federal Court of Australia Act 1976 (Cth) ss 37M and 37N

Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)

Patents Act1990 (Cth)ss 40(2)(a), 40(2)(aa), 40(3), 59, 60(4), 102(1), 102(2), 105(1A), 105(4) and 112A

Cases cited:

Autodesk Inc v Dyason (No 2) [1993] HCA 6; (1993) 176 CLR 300

Commissioner of Patents v Rokt Pte Ltd [2020] FCAFC 86; (2020) 277 FCR 267

Cytec Industries Inc. v Nalco Company [2018] APO 4.

Cytec Industries Inc. v Nalco Company [2019] APO 2

Cytec Industries Inc. v Nalco Company [2019] FCA 1800

Cytec Industries Inc. v Nalco Company [2021] FCA 970

Davies v Lazer Safe Pty Ltd [2019] FCAFC 65

Genetics Institute Inc v Kirin-Amgen Inc [1999] FCA 742; (1999) 92 FCR 106

Les Laboratoires Servier v Apotex Pty Ltd (2016) 247 FCR 61; [2016] FCAFC 27

Meat & Livestock Australia Limited v Cargill, Inc (No 2) (2019) 139 IPR 147; [2019] FCA 33

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 2) (2019) 139 IPR 424; [2019] FCA 154

Nichia Corporation v Arrow Electronics Australia Pty Ltd [2019] FCAFC 2; (2019) 175 IPR 187

Nutrasweet Australia Pty Ltd v Ajinomoto Co Inc (No 3) [2007] FCA 966; (2007) 73 IPR 282

Prince Alfred College Inc v ADC [2016] HCA 37; (2016) 258 CLR 134

Repipe Pty Ltd v Commissioner of Patents (No 3) [2021] FCA 31

ToolGen Incorporated v Fisher (No 3) [2024] FCA 539

Welch Perrin & Co Pty Ltd v Worrel [1961] HCA 91; (1961) 106 CLR 588

Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 111
Date of hearing: 8 June 2023; 15 June 2023; 14 December 2023
Counsel for the Appellant / Cross-Respondent: Mr C Dimitriadis SC, Mr BA Mee
Solicitor for the Appellant / Cross-Respondent: Allens
Counsel for the Respondent / Cross-Appellant: Mr JS Cooke SC, Ms M Evetts, Ms S Yates
Solicitor for the Respondent / Cross-Appellant: Spruson & Ferguson Lawyers Pty Limited

ORDERS

NSD 130 of 2019
BETWEEN:

CYTEC INDUSTRIES INC.

Appellant

AND:

NALCO COMPANY

Respondent

AND BETWEEN:

NALCO COMPANY

Cross-Appellant

AND:

CYTEC INDUSTRIES INC.

Cross-Respondent

ORDER MADE BY:

BURLEY J

DATE OF…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Cytec Industries Inc. v Nalco Company (No 4) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCA 1318
Decision Date

CaseChat Overview and Summary

The case of Cytec Industries Inc. v Nalco Company (No 4) involved a dispute over the validity of a patent application held by Nalco, with Cytec challenging the patent on several grounds. The matter was before the Federal Court of Australia, which was tasked with determining whether Nalco's application to amend its patent following an appeal under section 60(4) of the Patents Act 1990 (Cth) should be allowed. The legal issues before the court included whether the proposed amendments were allowable under section 102 of the Patents Act, whether the amendments overcame the deficiencies identified during the appeal, and the proper construction of the patent claims.

The court considered whether the proposed amendments adequately addressed the deficiencies in support and clarity of the description, which were central issues in the earlier appeal. The court found that the amendments did not sufficiently alter the meaning of the claims to avoid the issues of lack of support and lack of a clear and complete description. Specifically, the court held that the amendments failed to change the interpretation of the word "comprising" or the phrase "within a product mixture," and did not address the core issue that the technical contribution of the specification was not directed to isolating specific small molecules. The court also rejected Nalco's arguments concerning the hydrolysis construction of the claims.

Ultimately, the court refused Nalco's application to amend the patent, finding that the proposed amendments were not allowable under the Patents Act and did not sufficiently address the deficiencies identified in the earlier appeal. The court ordered the parties to confer and submit short minutes of order within 14 days, reflecting the terms of the judgment, and to outline any areas of disagreement if they were unable to reach an agreement.

Orders

Orders of the court

1. The parties confer and supply to the chambers of Justice Burley, within 14 days, short minutes of order giving effect to these reasons.

2. Insofar as the parties are unable to agree to the terms of the short minutes of order referred to in order 1, the areas of disagreement should be set out in mark-up.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Mr Bellwood and Professor Eastern joined in the preparation of a joint expert report for the purpose of the amendment application. They both gave oral evidence in concurrent session and were cross-examined on their evidence. 2.2 Nalco’s lay evidence Gareth Michael Dixon is a registered patent attorney and a Principal of Spruson & Ferguson Pty Ltd, the patent and trade mark attorneys associated with Spruson & Ferguson Lawyers Pty Ltd, the solicitors for Nalco. As of November 2021, Shelston IP Pty Ltd and Shelston IP Lawyers Pty Ltd, previously the solicitors for Nalco were acquired by Spruson & Ferguson. Mr Dixon affirmed two affidavits in relation to the amendment application. Mr Dixon was cross-examined about his evidence. He gives evidence about: what he understood, as Nalco’s patent attorney (and the advice actually given), to be the invalidity risk to the patent application in respect of the disclosure and support requirements before the commencement of the appeal proceedings; the history of and basis for the associated amendment applications before the APO. Duncan Roland Longstaff is a legal practitioner and Principal of Spruson & Ferguson Lawyers Pty Ltd, and prior to that was a Principal of Shelston IP Lawyers Pty Ltd. Since November 2019, Mr Longstaff has had the care and conduct of these proceedings on behalf of Nalco. Mr Longstaff affirmed four affidavits in relation to the amendment application. Mr Longstaff was cross-examined about his evidence. He gives evidence about: the nature and effect of the proposed amendments sought by the fifth proposed amendment; the history of amendments to and Cytec’s opposition of the patent application; the consideration given by Nalco or Shelston IP to the sufficiency and support issues the subject of the judgment prior to the filing of the fifth proposed amendment; and the basis for and effect of the sixth proposed amendment. Corey Ricardo Anthony is a Senior Intellectual Property Counsel of Ecolab Inc., the parent company of Nalco. Since May 2017, Dr Anthony has been responsible for prosecuting the patent application, instructing Spruson & Ferguson (previously Shelston IP) during the opposition before the APO and in the appeal proceeding before this Court. Dr Anthony affirmed one affidavit in relation to the amendment application and an earlier affidavit in the proceedings in relation to discovery. Nalco sought to read and rely on both affidavits. He was cross-examined about his evidence. In his second affidavit, Dr Anthony gives evidence about: the history of the proceedings before the APO and this Court, including correspondence between Nalco’s legal team as to the form and rationale of proposed amendments; and the consideration given by Nalco to the sufficiency and support issues the subject of the judgment. Eric Eugene DeMaster is the Assistant Chief Intellectual Property Counsel of Ecolab Inc. From August 2015 to May 2017, Mr DeMaster had responsibility for the prosecution of the patent application, including instructing Shelston IP. Mr DeMaster affirmed one affidavit in relation to the amendment application. He gave evidence about the history of the proceedings during that time, including the basis for the second proposed amendment. He was not cross-examined.

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established

Nor do I consider that the passage on page 34 of the specification (quoted at [82] above) provides a basis for reading down the language of amended claim 1. The examples are expressed to be given without limitation to the scope of the invention. Whilst the specification does make a distinction between hydrolysed and non-hydrolysed product mixtures, the language of the claims does not. That this was a clear choice on the part of the drafter is further apparent from the language of the current claim set, which in claim 16 provides for a “method according to claim 1, wherein the composition is hydrolyzed prior to being added to the Bayer process”. 5. CONSIDERATION OF THE GROUNDS OF OPPOSITION I have found above that the small molecule construction issue be determined in favour of Cytec such that the amended claims include within their scope a composition that includes only the identified small molecules within a product mixture, although a large number of other small molecules and polymers may also be included. I have also found that Nalco’s arguments in relation to the hydrolysis construction issue must be rejected. The finding in relation to the small molecule construction issue has the consequence that Cytec’s ground 4 does not arise, because its lack of clarity point is pleaded on the basis that Nalco’s construction is accepted, which it is not. The finding in relation to the hydrolysis construction issue has the consequence that ground 6A also does not arise, because the lack of best method ground pleaded is based on Nalco’s construction, which I have rejected. The remaining grounds concern the consequences of my findings in relation to the small molecule construction issue. Cytec submits that in light of this construction the amendment application must be determined adversely to Nalco on three separate alternative bases. First, that as a matter of discretion the amendment is futile and ought to be refused (ground 7), second, that the amendment is not allowable because as a result of the amendment the specification would claim matter that extends beyond that disclosed in the complete specification in breach of s 105(4) and s 102(1) (ground 5) and thirdly because as a result of the amendment the specification would not comply with the requirement of s 40(2)(a) that the specification disclose the invention clearly and be supported within the requirements of s 40(3) in breach of s105(4) and s 102(2)(b) (ground 6). For the reasons given below, I accept that each of these grounds applies to defeat the application to amend. 5.1 Lack of support and lack of clear and complete description The construction that I have determined in relation to the small molecule construction issue is one that is materially the same as that which I adopted in the judgment in section 5.2. In short, I concluded that the word “comprising” in current claim 1 is to be given the inclusive meaning defined in the body of the specification, with the consequence that claim 1 includes within its scope a product mixture formed from the reaction of A + GPS + E that consisted entirely of a single type of small molecule. I have reached the same conclusion in section 4.2 above albeit that instead of a single type of small molecule for amended claim 1 there are 13 specified small molecules, for amended claims 2 and 3 there are 14 specified small molecules and for amended claims 4 and 5 there are three such specified small molecules. Indeed, it seems to me that the ineluctable outcome of the reasoning set out in the judgment is that I should reach the same conclusion in relation to the amended claims. The amendments proposed by Nalco do not serve to afford any different meaning to the word “comprising” or the words “within a product mixture” in the context of the amended claims. Nor was there any material difference in the evidence concerning the fact that the technical contribution of the specification was not directed to the ability to isolate given small molecules – whether it be a single small molecule or a group of small molecules.